Metabolic specialistRank #8 of 12Prescribes

9amHealth

Item: 9amHealth
Rating: 7.3
Author: MyGLP Reviews

Virtual cardiometabolic clinic with bundled labs and pharmacy

Founded 2021 · San Diego, CA · Private · Website

7.3Adequate

Weighted score

Adequate

Reviewed September 19, 2026

PMPM benchmark

$34–$72

Category planning band — not a vendor quote. Excludes drug spend.

Our verdict

The best value proposition in the mid-market if the bundle economics work against your PBM. Verify that math first, and accept that the evidence base is still young.

Scorecard

How it scored

Scored against the published rubric. Weights are fixed before review and identical for every vendor.

How scoring works

Clinical rigor7.7

Prescriber credentials, titration protocol, comorbidity screening, and off-ramp planning.

Outcomes evidence6.6

Quality of published results: peer review, sample size, control group, and follow-up duration.

Cost control7.9

Ability to hold net pharmacy spend down: gating, biosimilar strategy, and risk sharing.

Data & reporting7.0

Eligibility-level reporting, claims feeds, and whether you can audit the vendor's own numbers.

Integration7.1

PBM, carrier, HRIS, and point-solution interoperability without custom engineering.

Member experience7.8

Time to first appointment, app quality, care-team continuity, and support responsiveness.

Analysis

What we found

9amHealth's bundling of labs and generic medications into a single PMPM is the most buyer-friendly pricing structure in this evaluation, and the generic-first protocol with pharmacist-led deprescribing gives it real cost-control mechanics. Treating the whole cardiometabolic panel also matches how these members actually present, rather than carving weight out artificially. The limitation is evidentiary maturity: the outcomes work is credible but self-published, and the enterprise track record is short compared with the established players.

Strengths

Bundled labs and generic medications make total cost genuinely predictable, which is rare here
Pharmacist-led deprescribing review is a structural cost lever most competitors lack entirely
Treats the full cardiometabolic panel rather than isolating weight, which fits how these members actually present

Limitations

Outcomes evidence is the thinnest among vendors scoring this well — white-paper only
Younger company with a shorter enterprise track record than most of this set
Bundle economics get less attractive if your PBM already delivers deep generic discounts

Best for

Mid-market employers who want predictable all-in pricing and a genuine generic-first clinical protocol.

Watch out

Model the bundle against your existing PBM generic pricing. For some buyers the bundle is a premium, not a saving.

The details

Commercial and clinical specifics

The facts you will need to build a comparison grid. Verify each against the vendor's own documentation before contracting.

Pricing

Model: Bundled per-member monthly including labs and generic medications
PMPM range: $34–$72
Setup fee: None
Medications included: Yes
Performance guarantees: Clinical guarantees available; savings guarantees at scale

Contract

Minimum lives: 500
Term: 12 months
Termination notice: 60 days

Eligibility

BMI threshold: BMI ≥ 27, or any cardiometabolic diagnosis
Prior authorization: Yes
Step therapy: Yes
Comorbidity required: No

Clinical model

Prescribes: Yes
Care team: Physicians, Nurse practitioners, Registered dietitians, Pharmacists
Titration protocol: Generic-first protocol with documented escalation criteria to branded GLP-1s
Off-ramp: Pharmacist-led deprescribing review at defined intervals
Formulary: Metformin, Semaglutide, Tirzepatide, Liraglutide, SGLT2 inhibitors, Statins, Antihypertensives

Outcomes evidence

Headline claim: Improvement across a combined cardiometabolic panel rather than weight alone, as reported by the company
Evidence level: Vendor-reportedMarketing figure with no published methodology. Treat as a claim, not a result.
Sample size: Not verified in a citation we could confirm
Follow-up: Not verified

Sources

9amHealthWe could not locate a peer-reviewed outcomes study for the programme during this review. Rated vendor-reported until one is verified.

Outcomes verified 2026-09-19. Pricing and contract figures on this page are category planning benchmarks, not vendor quotes — see methodology.

Integrations

PBMs: CVS Caremark, Express Scripts
Carriers: Aetna, Cigna, UnitedHealthcare
HRIS: Workday, ADP, BambooHR
Eligibility file: Flat file, weekly cadence

Formulary

9amHealth by medication

How a vendor positions each molecule reveals more about its cost discipline than any single score. First-line means an eligible member can start immediately; escalation means a documented lower-cost trial comes first.

9amHealth Reviews Semaglutide

GLP-1 receptor agonist

Escalation only

Reached only after a generic-first protocol with documented escalation criteria. Because labs and generic medications are bundled into the PMPM, 9amHealth carries real financial exposure when members escalate — a rare structural alignment.

Read pairing

9amHealth Reviews Tirzepatide

Dual GIP/GLP-1 receptor agonist

Escalation only

Top of the escalation ladder, behind both generic therapy and, in most cases, semaglutide. Pharmacist-led deprescribing review at defined intervals applies here as it does across the formulary.

Read pairing